SONN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Sonnet BioTherapeutics Insider Trading History Chart

Sonnet BioTherapeutics Share Price & Price History

^$1.25

▼ -0.02 (-1.57%)

As of 04/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Sonnet BioTherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Susan Dexter	Insider	Buy	454	$15.40	$6,991.60	1,530
5/30/2023	Albert D Dyrness	Director	Buy	1,057	$10.34	$10,929.38	1,316
5/17/2023	Nailesh Bhatt	Director	Buy	1,136	$5.06	$5,748.16	1,396
5/15/2023	Pankaj Mohan	CEO	Buy	16,890	$4.84	$81,747.60	25,151

SEC Filings (Institutional Ownership Changes) for Sonnet BioTherapeutics (NASDAQ:SONN)

9.45% of Sonnet BioTherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Sonnet BioTherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Two Sigma Investments LP	19,203	$28K	0.0%	N/A	0.630%
2/11/2025	Virtu Financial LLC	39,647	$58K	0.0%	N/A	1.300%
8/15/2024	Armistice Capital LLC	272,000	$0.26M	0.0%	N/A	8.740%
7/27/2023	Virtu Financial LLC	86,624	$42K	0.0%	N/A	0.315%
5/19/2023	Anson Funds Management LP	1,760,000	$0.63M	0.1%	N/A	6.405%
11/7/2022	Virtu Financial LLC	26,914	$40K	0.0%	N/A	0.622%
8/2/2022	Advisory Services Network LLC	130,525	$37K	0.0%	+158.3%	0.215%
5/10/2022	Campion Asset Management	90,612	$34K	0.0%	N/A	0.150%
8/16/2021	State Street Corp	62,688	$99K	0.0%	N/A	0.253%
8/13/2021	Vanguard Group Inc.	701,634	$1.11M	0.0%	+416.0%	2.834%
5/19/2021	Virtu Financial LLC	65,106	$0.15M	0.0%	N/A	0.371%
5/18/2021	Citadel Advisors LLC	113,264	$0.26M	0.0%	N/A	0.534%
5/18/2021	Jane Street Group LLC	17,304	$39K	0.0%	N/A	0.099%
5/17/2021	Price T Rowe Associates Inc. MD	45,100	$0.10M	0.0%	N/A	0.257%
5/13/2021	Bank of New York Mellon Corp	20,399	$46K	0.0%	N/A	0.116%
5/7/2021	BlackRock Inc.	255,761	$0.58M	0.0%	+3.7%	1.457%
3/26/2021	Susquehanna International Group LLP	15,434	$34K	0.0%	N/A	0.088%

Data available starting January 2016

See Full Table

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Today's Range

Now: $1.25

$1.25

$1.70

50 Day Range

MA: $1.49

$1.27

$1.83

52 Week Range

Now: $1.25

$1.22

$16.80

Volume

206,770 shs

Average Volume

375,353 shs

Market Capitalization

$3.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Who are the company insiders with the largest holdings of Sonnet BioTherapeutics?: Sonnet BioTherapeutics' top insider investors include:
Pankaj Mohan (CEO)
Susan Dexter (Insider)
Nailesh Bhatt (Director)
Albert D Dyrness (Director)
Learn More about top insider investors at Sonnet BioTherapeutics.